medigraphic.com

2011, Number 1

Cir Gen 2011; 33 (1)

Sensitivity and specificity of CA-19-9 for the diagnosis of pancreatobiliary neoplasms in patients with obstructive-origin jaundice

Ortiz HV, Chapa AO, Hernández MBI, Aguilera SAF, Cruz MR

Language: Español
References: 26
Page: 14-20
PDF size: 289.90 Kb.


ABSTRACT

Objective: To describe the biological behavior of the tumor marker CA 19-9 in cholestasis to determine its usefulness for the diagnosis of pancreatobiliary cancer in patients with obstructive-origin jaundice. Sede: General Hospital of Mexico, third level health care center. Mexico City.
Design: Prospective, longitudinal, and comparative study.
Statistical analysis: T and Kolmogorov Smirnov tests for independent samples; diagnostic value test (sensitivity, specificity, and global value). Analysis with ROC curves was performed to identify sensitivity and specificity at the different cutting points.
Patients and methods: We included 54 patients with a diagnosis of obstructive-origin jaundice. They were divided in two groups according to the final diagnosis, malignant disease vs. benign disease. Serum CA 19-9 was determined at admittance and once cholestasis had been resolved, and the levels were correlated with the final diagnosis.
Results: In jaundice patients, with a cut point of 60 U/mL to distinguish between malignant and benign disease, the CA 19-9 marker has a sensitivity of 80% and a specificity of 90%. Once cholestasis had been resolved with a cut point of 39 U/mL, sensitivity was of 71% with a 96% specificity. Normalization of the marker after bile drainage is highly suggestive of benign pathology. The persistence of high levels (higher than 60 U/mL) is highly suggestive of malignancy with a sensitivity of 58% and specificity of 100%.
Conclusions: Cholestasis does modify the sensitivity and specificity of the CA 19-9 marker for the diagnosis of pancreatobiliary malignant neoplasms; therefore, in the presence of obstructive-origin jaundice, the 60 U/mL cut point offers a sensitivity of 80% with a specificity of 90% to be able to distinguish between malignant and benign disease. Once cholestasis has been resolved, persistence of high levels is highly suggestive of malignancy.

References

  1. Brown KM. Multidisciplinary approach to tumors of the pancreas and biliary tree. Surg Clin North Am 2009; 89: 115-131.

  2. Instituto Nacional de Estadística y Geografía, Capítulo 4. Salud, en mujeres y hombres en México 2009, 13a Edición, Editado por Instituto Nacional de Estadística y Geografía, México D.F., 2009, 82-84.

  3. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamanti MS. National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246: 173-180.

  4. Orr RK. Outcomes in pancreatic cancer surgery. Surg Clin North Am 2010; 90: 219-234.

  5. Hartwig W, Schneider L, Diener MK, Bergmann F, Büchler MW, Werner J. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg 2009; 96: 5-20.

  6. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.

  7. Urban D, Catane R. Serum tumor markers in oncology. Isr Med Assoc J 2009; 11: 103-4.

  8. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971.

  9. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Research 1987; 47: 5501-5503.

  10. von Rosen A, Linder S, Harmenberg U, Pegert S. Serum levels of CA 19-9 and and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993; 8: 160-165.

  11. McPherson RA, Pincus MR. Henry’s Clinical Diagnosis and Management by Laboratory Methods, 21st ed, Chapter 34, Immunotheraphy, W. B. Saunders Company, 2006.

  12. Marcouizos G, Ignatiadou E, Papanikolaou G, Ziogas D, Fatouros M. Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases Journal 2009; 2: 6662.

  13. Yoshida EM, Scudamore CH, Erb SR, Owen DA, Silver HK. Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis. Can J Surg 1995; 38: 83-86.

  14. Ulla-Rocha JL, Alvarez-Sanchez MV, Paz-Esquete J, Fernandez-Salgado E, Alvarez-Alvarez C, Vazquez-Sanluis MJ, et al. Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation. JOP 2007; 8: 191-197.

  15. Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008; 53: 3213-3217.

  16. Wu JT, Olson J, Walker K. Tumor markers CA 19-9 and CA 195 are also useful as markers for cystic fibrosis. J Clin Lab Anal 1992; 6: 151-161.

  17. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker CA 19-9. Clin Chem 1983; 29: 549-552.

  18. Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician 2004; 69: 299-304.

  19. Tanaka N, Okada S, Ueno H, Okusaka T, Ikeda M. The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer. Pancreas 2000; 20: 378-381.

  20. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-1946.

  21. Haglung C, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197-202.

  22. Goonetilleke KS, Siriwardena AK. Systemic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266-270.

  23. Mery CM, Duarte-Rojo A, Paz-Pineda F, Gomez E, Robles-Diaz G. ¿Modifica la colestasis la utilidad clínica del CA 19-9 en cáncer pancreatobiliar? Rev Invest Clin 2001; 53: 511-517.

  24. Tessler DA, Catanzaro A, Velanovich V, Havstad S, Goel S. Predictors of cancer in patients with pancreatic malignancy without a tissue diagnosis. Am J Surg 2006; 191: 191-197.

  25. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreatobiliary disease. Hepatobiliary Pancreat Dis Int 2009; 8: 620-626.

  26. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA 19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009; 198: 333-339.

2020     |     www.medigraphic.com